METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA8509-LBA8509
Keyword(s):
LBA8509 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.
2017 ◽
Vol 35
(17)
◽
pp. 1905-1912
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA8005-LBA8005
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA7507-LBA7507
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA9514-LBA9514
2018 ◽
Vol 36
(6_suppl)
◽
pp. TPS530-TPS530
◽
2008 ◽
Vol 26
(35)
◽
pp. 5748-5754
◽
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA4518-LBA4518
2019 ◽
Vol 37
(4_suppl)
◽
pp. 711-711
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA5000-LBA5000
Keyword(s):